Added to YB: 2025-11-12
Pitch date: 2025-11-06
NVO [neutral]
Novo Nordisk A/S
+2.04%
current return
Author Info
Fat Alpha Value Investing is a podcast that inveterviews top value investors who share their ideas. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 301.25
Price Target
332.00 (+8%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
Novo's problem isn't the drugs - Conservative FCF scenarios
NVO (overview): Stock dropped -4.5% on results. 2025 guidance: DKK 302-306B revenue (+4-5.5%), DKK 137B adj EBIT (44.6% margin vs 48.2% in 2024). High capex/intangibles spending pressures FCF to DKK 30-37B. Mgmt says nearing peak spend; normalized FCF could reach DKK 59-86B. DCF values stock DKK 332-381 vs current DKK 300.
Read full article (3 min)